| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Preclinical, clinical trial and other costs |
|
$ |
2,142,229 |
|
|
$ |
1,261,720 |
|
|
$ |
3,339,263 |
|
|
$ |
2,293,001 |
|
| Research and development personnel expense(1) |
|
|
305,057 |
|
|
|
468,724 |
|
|
|
696,504 |
|
|
|
976,554 |
|
| Research and development personnel
expense |
|
|
305,057 |
|
|
|
468,724 |
|
|
|
696,504 |
|
|
|
976,554 |
|
| General and administrative personnel expense(2) |
|
|
628,330 |
|
|
|
445,620 |
|
|
|
1,302,167 |
|
|
|
964,409 |
|
| General and administrative
personnel expense |
|
|
628,330 |
|
|
|
445,620 |
|
|
|
1,302,167 |
|
|
|
964,409 |
|
| Administrative and facilities expense(3) |
|
|
875,167 |
|
|
|
905,960 |
|
|
|
1,459,839 |
|
|
|
1,657,658 |
|
| Administrative and facilities
expense |
|
|
875,167 |
|
|
|
905,960 |
|
|
|
1,459,839 |
|
|
|
1,657,658 |
|
| Other income, net |
|
|
(16,865 |
) |
|
|
(71,698 |
) |
|
|
(29,450 |
) |
|
|
(154,915 |
) |
| Total |
|
$ |
3,933,918 |
|
|
$ |
3,010,326 |
|
|
$ |
6,768,323 |
|
|
$ |
5,736,707 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $8,613 and $45,583 for the three months ended
June 30, 2025 and 2024, respectively, and $55,333 and $76,704 for the six months ended June 30, 2025 and 2024, respectively. |
| |
|
|
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $122,655 and $40,309 for the three months
ended June 30, 2025 and 2024, respectively, and $245,310 and 79,180 for the six months ended June 30, 2025 and 2024, respectively,
and are net of reimbursements received from CorLyst, LLC. |
| |
|
|
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|